(Q61692534)
Statements
Bevacizumab (B) plus low-doses immunotherapy (IT) plus chemotherapy (CT) (BIC) in metastatic renal cell cancer (mRCC): Antitumor effects and variations of T-regulatory cells (Treg) and other T lymphocytes subsets. A study of the Italian Oncology Grou (English)
0 references
20 May 2008
0 references
26
0 references
15_suppl
0 references
5121-5121
0 references